论文部分内容阅读
目的探讨超声造影容积成像技术在125Ⅰ粒子治疗肝恶性肿瘤中的应用价值。方法12例原发性肝癌(HCC)患者125Ⅰ粒子治疗后,采用超声造影剂SonoVue、飞利浦IU-22超声诊断仪、三维超声技术和Qlab软件对治疗后的病灶进行超声容积成像检查。结果125I粒子治疗后28个病灶行超声造影容积成像,肿瘤容积灭活率为84.32%,与增强CT检查结果相同,肿瘤容积灭活率的诊断率明显高于常规彩超的70.15%;残留肿瘤的几何形态与三维治疗计划系统(TPS)描绘相近。结论超声造影容积成像可准确定量评估125I粒子治疗肝恶性肿瘤的效果,描绘残余病灶的三维几何形态,对残余病灶的补充治疗有重要的临床价值。
Objective To investigate the value of ultrasound contrast volume imaging in the treatment of hepatic malignancies with 125 Ⅰ particles. Methods Twenty-two patients with primary hepatocellular carcinoma (HCC) were enrolled in this study. SonoVue, Philips IU-22, three-dimensional ultrasound and Qlab software were used to perform ultrasound volume imaging. Results The volume of tumor volume deactivation was 28.32% in 28 lesions after 125I particle treatment. The diagnostic rate of tumor volume inactivation rate was significantly higher than that of conventional color Doppler ultrasound in the same way as enhanced CT examination. The residual tumor The geometry is similar to the three-dimensional treatment planning system (TPS) plot. Conclusion Contrast-enhanced ultrasound imaging can accurately and quantitatively evaluate the effect of 125I particles on the treatment of hepatic malignancies and describe the three-dimensional geometric shapes of the residual lesions. It is of great clinical value in the treatment of residual lesions.